Prevalence and Risk Factors of Significant Fibrosis in CHB Patients with Concurrent MASLD

Introduction and Objectives Significant fibrosis is an indicator of clinical intervention for both chronic hepatitis B (CHB) and metabolic dysfunction-associated steatotic liver disease (MASLD). There remains a paucity of data regarding the clinical impact of biopsy-defined MASLD on significant fibrosis in CHB patients. The current study aims to elucidate whether patients with concomitant MASLD are at higher risk of significant fibrosis in patients with CHB. Patients and Methods This retrospective research of two tertiary hospitals comprised 1818 patients between 2009 and 2021 with CHB and hepatic steatosis who had not received antiviral therapy. Pathologic findings by liver biopsy were contrasted between CHB group (n=844) and CHB + MASLD (n=974) group. METAVIR values of F≥2 were used to categorize significant fibrosis. Results Patients with CHB + MASLD had more significant fibrosis (35.5% vs. 23.5%, p<0.001) than CHB group. The presence of MASLD [adjusted odds ratio (aOR) 2.055, 95% confidence interval (CI) 1.635-2.584; p<0.001] was strongly associated with significant fibrosis in all CHB patients. There was a trend for patients with more cardiometabolic risk factors (CMRFs) to have a higher prevalence of significant fibrosis:(25.7% in CMRF1 subgroup v.s. 34.9% in CMRF2 subgroup v.s. 53.7% in CMRF≥ 3 subgroup, p<0.001). Patients with CMRF≥3 had a three-fold higher significant fibrosis than those with just one CMRF. Conclusions MASLD was associated with higher fibrosis stage in patients with CHB. Early detection and intervention are crucial to patients with three or more cardiometabolic risk factors.